Showing results (281-290 of 531) with videos related to

Sort By:
Pageof 54
The Journal of Thoracic and Cardiovascular Surgery|March 7, 2006
Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF studyNicholas G Smedira, Cornelius M Dyke, Andreas Koster, et al.
The American Journal of Cardiology|December 15, 1995
Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary interventionR A Harrington, N S Kleiman, K Kottke-Marchant, et al.
The American Journal of Medicine|July 11, 2002
Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularizationEric J Topol, A Michael Lincoff, Dean J Kereiakes, et al.
Journal of Interventional Cardiology|August 26, 2009
Outcomes of patients with coronary artery perforation complicating percutaneous coronary intervention and correlations with the type of adjunctive antithrombotic therapy: pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trialsJacob A Doll, Eugenia Nikolsky, Gregg W Stone, et al.
Circulation Research|December 1, 1993
Differences in cardioprotective efficacy of adrenergic receptor antagonists and Ca2+ channel antagonists in an animal model of dilated cardiomyopathy. Effects on gross morphology, global cardiac function, and twitch forceM G Glass, F Fuleihan, R Liao, et al.
European Journal of Preventive Cardiology|February 16, 2026
Effect of bempedoic acid on cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver diseaseVivian D de Jong, Steven E Nissen, William J Sasiela, et al.
JAMA|August 21, 2003
Prevalence of conventional risk factors in patients with coronary heart diseaseUmesh N Khot, Monica B Khot, Christopher T Bajzer, et al.
JAMA|July 4, 2001
Risk of stroke associated with abciximab among patients undergoing percutaneous coronary interventionK M Akkerhuis, J W Deckers, A M Lincoff, et al.
European Journal of Preventive Cardiology|February 11, 2017
The haemoglobin glycation index as predictor of diabetes-related complications in the AleCardio trialSigrid Cj van Steen, Ilse C Schrieks, Joost Bl Hoekstra, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 22, 2005
Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury modelKai Wang, Zhongmin Zhou, Ming Zhang, et al.
Pageof 54